# A Review of Selected Federal Vaccine and Immunization Policies, Based on Case Studies of Pneumococcal Vaccine


September 1979

NTIS order #PB80-116106

# A REVIEW OF SELECTED FEDERAL VACCINE AND IMMUNIZATION POLICIES

BASED ON CASE STUDIES OF PNEUMOCOCCAL VACCINE

SECTIONAL DESCRIPTION



# Library of Congress Catalog Card Number 79-600165

For sale by the Superintendent of Documents, U.S. Government Printing Office

Washington, D.C. 20402 Stock No. 052-003 -00701-1

# **FOREWORD**

This work originated in April 1978 as a background study in OTA'S Congressional Fellowship Program. The study initially was limited to an analysis of the benefits and costs of pneumococcal vaccine, with particular emphasis on vaccine reimbursement under Medicare for the elderly. As a result of encouragement by several reviewers, the scope of investigation was broadened substantially to include three other areas of vaccine policy concerns: research, development, and production; safety and efficacy; and 1iability. Cost-effectiveness analysis was selected to assess benefits and costs, and the entire report was incorporated into a larger OTA study entitled Cost-Effectiveness of Medical Technologies. This report is the first of six documents to be published as a part of the larger cost-effectiveness study.

A Review of Selected Federal Vaccine and Immunnization Policies was prepared by OTA staff in consultation with several authorities in the relevant subject areas. The authors' professional backgrounds include training in pubic health, pharmacy, economics, law, medicine, public administration, public policy, and political science. Consultants included representatives from pharmaceutical companies, including Eli Lilly and Company, Merck Sharp and Dohme, and Lederle Laboratories; Government agencies, including the Bureau of Biologics (BOB), Center for Disease Control (CDC), National Institute of Allergy and Infectious Diseases (NIAID), National Center for Health Statistics (NCHS), and Bureau of the Census; and academic institutions, in particular, Duke University, Harvard University, the University of Pennsylvania, and the University of California at San Francisco.

Drafts of the report were reviewed by members of two OTA advisory bodies: the Health Program Advisory Committee and the Cost-Effectiveness of Medical Technologies Advisory Panel. Various drafts also were reviewed by approximately so other individuals representing a wide range of professional disciplines. We were grateful for these many contributions to the work.

~ JOHN H. GIBBONS

John H Sibbour

Director

### OTA HEALTH GROUP STAFF

Joyce C. Lashof, Assistant Director Health and Life Sciences Division

H. David Banta, Health Group Manager

Michael A. Riddiough, Project Director

Jane Sisk Willems, *Health Econonmics and Policy* Co-Project Director (April-September 1978)

Claudia Sanders, *Health Policy*Lawrence Miike, *Vaccine Liability*John Bell, *Computer Modeling*Clyde Behney, *Health Policy* 

### **Editorial Staff**

Kerry B. Kemp, Editor and Writer'

Page S. Gardner, Editor

### **Administrative Staff**

Virginia Cwal ina

Shirley Ann Gayheart

William S. Burnett

### **OTA PUBLISHING STAFF**

John C. Holmes, *Publishing Officer*Kathie S. Boss Joanne Heming

<sup>\*</sup> Independent contractor

### OTA HEALTH GROUP ADVISORY COMMITTEE

Frederick C. Robbins, Chairman

Dean, School of Medicine, Case Western Reserve University

Stuart H. Altman

Dean

Floremce Heller School Brandeis University

Robert M. Ball

Senior Scholar Institute of Medicine National Academy of Sciences

Bernard Barber

Professor

Department **Of** Sociology Barnard College Columbia University

Lewis H. Butler

Adjunct Professor of Health Policy Health Policy Program University of California

Kurt Deuschle

Professor of Community Medicine Mount Sinai School of Medicine

Rashi Fein

Professor of tile Economics **Of** Medicine Center for Comunity Health and Medical Care Harzard Medical **School** 

Melvin A. Glasser

Director Social Security Department United Auto Workers Sidney S. Lee

Associate Dean Community Medicine McGill Unversity

Mark Lepper

Vice President for Evaluation Rush-Presbyterian Medical School St. Luke's Medical Center

C. Frederick Mosteller

Professor and Chairman Department of Biostatistics School of Public Health Harvard University

Beverlee Myers

Director
Department of Health Services
State of California

Helen Ewing Nelson

President Consumer Research Foundation Mill Valley, Calif.

Charles A. Sanders

General Director Massachusetts General Hospital

Kerr L. White

Deputy Director of Health Sciences Rockefeller Foudation

# COST-EFFECTIVENESS OF MEDICAL TECHNOLOGIES ADVISORY PANEL MEMBERS

John R. Hogness, Chairman President, Association for Academic Health Centers

Stuart H. Altman

Dean

Florence Heller School Brandeis University

James L. Bennington

Chairman

Department of Anatomic Pathology and Clinical Laboratories Children's Hospital San Francisco, Calif.

John Chase

Associate Dean for Clinical Affairs University of Washington School of Medicine

Joseph Fletcher

Visiting Scholar Medical Ethics School of Medicine University of Virginia

Clark C. Havighurst

Professor of Law School of Law Duke University Sheldon Leonard

Mnager

Regulatory Affairs

General Electric Company

Barbara J. McNeil

Department of Radiology Peter Bent Brigham Hospital

Robert H. Moser

Executive Vice President American College of Physicians

C. Frederick Mosteller

Chirman

Department of Biostatistics Harward University

Robert M. Sigmond

Advisor in Hospital Affairs

Blue Cross and Blue Shield Associates

Jane Sisk Willems

V.A. Scholar

Veterans Administration

# **ACKNOWLEDGMENTS**

Several people provided valuable assistance in the preparation of this report. Individuals at the National Center for Health Statistics (NCHS), in particular, were very instrumental in developing data sets for the cost-effectiveness analysis. While OTA must assume ultimate responsibility for the content of this report, it greatly appreciates the contributions of—among many others—the following individuals:

Clarence A. Abramson Senior Counsel Merck and Company, Inc. Rahway, N.J.

Robert Austrian, M.D. Department of Research Medicine University of Pennsylvania School of Medicine Philadelphia, Pa.

Michael Beatrice, R. Ph., M.S. Bureau of Biologics Food and Drug Administration Bethesda. Md.

Claire Broome, M.D. Center for Disease Control Atlanta. Ga.

David W. Fraser, M. D., Center for Disease Control Atlanta. Ga.

Donald Hill Bureau of Biologics Food and Drug Administration Bethesda, Md.

James Hill, Ph.D.
National Institute of Allergy and
Infectious Diseases
Bethesda, Md.
Maurice Hilleman, Ph. D., D. SC.
Director

Merck Institute for Therapeutic Research

West Point, Pa.

Alan R. Hinman, M. D., M.P.H. Center for Disease Control Atlanta, Ga.

Mark Hornbrook, Ph.D. National Center for Health Services Research Hyattsville, Md.

Irving S. Johnson, Ph.D. Vice President of Research Eli Lilly and Company Indianapolis, Ind.

Joel Kavet, D. SC.
Department of Health, Education, and Welfare
Rockville, Md.

Kenneth Manton, Ph.D. Duke University Durham, N.C,

Barbara J. McNeil, M. D., Ph.D. Harvard Medical School Boston, Mass.

Harry M. Meyer, Jr., M.D. Director Bureau of Biologics Food and Drug Administration Bethesda, Md.

Elena Nightingale, M.D. Institute of Medicine Washington, D.C. Paul D. Parkman, M.D.
Deputy Director
Bureau of Biologics
Food and Drug Administration
Bethesda. Md.

Frederick C, Robbins, M.D. Dean, School of Medicine Case Western Reserve University Cleveland, Ohio

John Robbins, M.D. Bureau of Biologics Food and Drug Administration Bethesda, Md.

Donald Shepard, Ph.D. Harvard School of Public Health Boston, Mass.

Eric Stollard Duke University Durham, N.C.

Judith Wagner, Ph.D. Urban Institute Washington, D.C.

Ronald Wilson National Center for Health Statistics Department of Health, Education, and Welfare Hyattsville, Md.